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The identification of target proteins  binding bioactive small 
molecules is an essential task in drug development that can 
extend the understanding of mechanisms and provide information 
for designing new drug candidates.1-9 Among many approaches 
to identify cellular targets of bioactive molecules, biochemical 
affinity purification using synthetic affinity probes that mimic the 
structure of the bioactive compounds is a straightforward and 
powerful method for identifying target molecules. Recently, 
photoaffinity labeling has been considered a more efficient 
variant of this method, as it can enrich for low-abundance or 
transiently-interacting targets.10-14 So far, there have been a 
number of successful examples that have determined the target 
molecules and identified the binding site through the formation 
of a covalent bond between the ligand and the specific protein.15-
23 In general, photoaffinity probes contain three functional 
groups: a bioactive scaffold, a photoreactive group and a reporter 
tag.24 A biotin tag is widely employed as a reporter tag because it 
binds streptavidin or avidin with extremely high affinity. 
Cremastranone (1), a naturally occurring homoisoflavanone is 
reported to have antiangiogenic activity with some selectivity for 
blocking proliferation of human retinal endothelial cells over 
other ocular cell types.25-28 It inhibits ocular angiogenesis, 
without substantial toxicity, in mouse models of laser-induced 
choroidal neovascularization (L-CNV) and oxygen-induced 
retinopathy (OIR). These animal models  recapitulate features of 
the blinding eye diseases wet age-related macular degeneration 
and retinopathy of prematurity, respectively. Cremastranone 
impinges on multiple signaling pathways. It induces expression 
of p21WAF1 (CDKN1A), which inhibits the cyclin-dependent 
kinase Cdc2 (CDK1).29 It also blocks prostaglandin synthesis and 
decreases activation of the mitogen activated protein kinases.30, 31 
Finally, it blocks nuclear translocation of NF-κB and production 
of inflammatory cytokines.25, 31, 32 Seeking more potent and 
selective compounds than cremastranone, we identified SH-
11037 which is observed to have novel antiangiogenic activity 
against human retinal microvascular endothelial cells (HRECs) 
and blocks neovascularization in the OIR and L-CNV models.27, 
33 Although the studies of mechanisms and medicinal chemistry 
could contribute to many therapeutic facets of the antiangiogenic 
homoisoflavonoids, their exact mechanisms of action and cellular 
targets remain unknown, so the search for direct interacting 
proteins is valuable.34, 35 Herein we report design and synthesis of 
homoisoflavonoid-biotin conjugates for inhibiting proliferation 






Cremastranone (1), a naturally occurring homoisoflavonoid, inhibited angiogenesis in vitro and 
in vivo. We developed an analogue SH-11037 (2) which is more potent than cremastranone in 
human retinal microvascular endothelial cells (HRECs) and blocks neovascularization in animal 
models. Despite its efficacy, the mechanism of this compound is not yet fully known. In the 
course of building on a strong foundation of SAR and creating a novel chemical tool for target 
identification of homoisoflavonoid-binding proteins, various types of photoaffinity probes were 
designed and synthesized in which benzophenone and biotin were attached to 
homoisoflavanonoids usin g PEG linkers on either the C-3' or C-7 position. Notably, the 
photoaffinity probes linking on the phenol group of the C-3' position retain excellent activity of 
inhibiting retinal endothelial cell proliferation with up to 72 nM of GI50. 
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of endothelial cells and identifying targets, adapting a synthetic 
strategy we previously employed to generate homoisoflavanones. 
 On the basis of our SAR investigations in which the A and B-
ring modifications of homoisoflavonoids with trimethoxy and 
Boc-phenylalanyl groups, respectively, had the most beneficial 
effects on its activities and selectivities, trifunctional 
photoaffinity probes were designed. We synthesized three kinds 
of photoaffinity probes (3~5) by linking a trimethoxy derivative 
of cremastranone and peptidylated active analog SH-11037 (2) to 
benzophenone and biotin (Figure 1) plus a control compound 
which lacks the homoisoflavanone moiety, for the future goal of 
detecting proteins that interact with the homoisoflavonoid-
labeled photoaffinity probes in cell lysates. In particular, we 
modified the homoisoflavanone scaffold at both C-7 and C-3' 
position with a benzophenone photoreactive group for 
crosslinking and a biotin reporter group through polyethylene 
glycol (PEG) as a linker. Thus, it was initially considered to 
prepare a photoaffinity reagent linking on the phenolic OH group 
of the C-3' position. It has been noted that the selected 
substituents such as N-Boc phenylalanyl moiety, which is added 
to the C-3' position of homoisoflavanone, are essential for the 
improved antiangiogenic effect. However, because it is uncertain 
where a linker might impinge on function, we anticipated that 
SH-11037 (2) could also be modified at the para-position of the 
phenylalanyl group as well as C-7 without a significant loss of 
activity by elongating a tethered biotin moiety with hydrophilic 
groups. Unfortunately, the introduction of a tether to the site of 
the NHBoc group in SH-11037 (2) was proven to be problematic 
due to the low reactivity of the amino group and instability of the 
ester group in the course of Boc-deprotection or linking with a 
carbamate. 
The synthesis of intermediate 10 is outlined in Scheme 1.24, 36  
Similar to the procedures reported previously, the synthesis of 
biotinylated benzophenone was commenced with two different 
alkylations of 4,4'-dihydroxybenzophenone, which was treated 
with propargylic bromide and K2CO3, followed by DIAD-
mediated Mitsunobu reaction using 3-(Boc-amino)-1-propanol to 
afford the resulting bis-ether 7. The azide 8 which was obtained 
from treatment of commercially available p-nitrophenyl ester of 
biotin (Biotin-ONp) with N3-PEG3-CH2CH2NH2  was coupled 
with bis-ether 7 by Cu-catalyzed Huisgen 1,3-dipolar 
cycloaddition,37 followed by the treatment of the resulting 1,2,3-
triazole 9 with TFA to afford benzophenone-linked biotin 
intermediate 10 in good yield. In future target identification 
studies, 10 can also be utilized as a negative control compound 
which lacks the homoisoflavanone moiety. 
To prepare the first photoaffinity probe 3, the bioactive and 
racemic 3-benzyl-4-chromanone (±)-11 was chosen as a starting 
material (Scheme 2).25-27 The phenolic OH on the C-3' position 
Figure 1. Structures of cremastranone (1), homoisoflavanone analogue SH-
11037 (2) and photoaffinity probes (3~5). Bp: benzophenone, Bt: biotin. 
Scheme 1. Synthesis of benzophenone-linked biotin compound (10). Reagen
ts and conditions: a) K2CO3, propargylic bromide, acetone, 82%; b) DIAD, B
oc-amino-propanol, PPh3, THF, 70%; c) 11-azido-3,6,9-trioxaundecan-1-ami
ne, iPr2NEt, CH2Cl2, 49%; d) CuSO4·5H2O, sodium ascorbate, t-BuOH/H2O, 
40%; e) TFA, CH2Cl2, 72%. 
Scheme 2. Synthesis of photoaffinity probe (3). Reagents and conditions: a) t-butyl bromoacetate, K2CO3, acetone, reflux, 95%; b) TFA, CH2Cl2, 
70%; c) 10, HBTU, iPr2NEt, DMF, 30%. 
was alkylated with tert-butyl bromoacetate under basic 
conditions, followed by the acidic treatment of the ester 12 to 
afford the carboxylic acid 13. Finally, the carboxylic acid 13 was 
coupled with the intermediate 10 by HBTU-mediated amidation 
to provide the desired photoaffinity probe 3 in moderate yield. 
For the photoaffinity probes modified at the para-position of 
the phenylalanyl group of 2, Boc-Tyr(Bn)-OH was introduced 
into compound 11 at the C-3' position by using EDCI (Scheme 
3). The debenzylation of the ester 14 afforded the resulting 
compound 15, which has a free OH group. The alkylation of 15 
with benzyl bromoacetate and subsequent hydrogenolysis under 
H2 and Pd/C generated the carboxylic acid 16. In the end, the 
carboxylic acid 16 was coupled with the intermediate 10 by 
HBTU-mediated amidation to afford the desired photoaffinity 
probe 4a in good yield.  
We next investigated the synthesis of an amide-containing 
photoaffinity probe, which might have increased stability 
compared to the ester probe 4a. This amide compound 4b was 
synthesized from homoisoflavanone 1727 having an amino group 
on the C3' position to which Boc-Tyr(Bn)-OH was added by 
EDCI-mediated amidation (Scheme 4). The resulting amide 18 
was treated with H2 and Pd/C to generate phenol 19. With phenol 
19 in hand, the alkylation with benzyl 4-bromobutyrate followed 
by debenzylation provided the carboxylic acid 20. Finally, the 
carboxylic acid 20 was coupled with the intermediate 10 by 
HBTU-mediated amidation to afford the desired photoaffinity 
probe 4b in good yield.  
The linking site of the final photoaffinity probe was different 
from that of the previous probes. Thus benzophenone-linked 
biotin could be attached at the C-7 position of 2 using our 
synthetic approach to cremastranone (Scheme 5). According to 
the procedures reported previously,27 the known acetophenone 21 
as a starting material was converted to 7-hydroxy-5,6-dimethoxy-
4-chromanone 22 via 2 steps in good yield. The C-7 alkylation of 
the compound 22 with benzyl 4-bromobutyrate provided the 
compound 23. Subsequently, the aldol condensation of 23 with 
isovanillin under acidic conditions gave the unstable 3-
benzylidene-4-chromanone 24. EDCI-mediated esterification of 
24 with Boc-Phe-OH and the catalytic hydrogenation reaction 
using H2, Pd/C resulted in the removal of the benzyl group and 
the saturation of the double bond to give the desired 
homoisoflavanone 25 having butyric acid at the C-7 position. The 
acid 25 was coupled with the intermediate 10 by HBTU-
mediated amidation to afford the final photoaffinity probe 5 in 
moderate yield. 
It is obviously important that the synthesized probes retain 
potency in biological assays. Therefore, we tested the anti-
proliferative activity of the probes as well as intermediates on 
human retinal microvascular endothelial cells (HRECs) and 
human umbilical vein endothelial cells (HUVECs). We also 
measured the endothelial cell specificity of these compounds by 
measuring their effects on the proliferation of non-endothelial 
ocular cell lines, Y79 (retinoblastoma cell line), 92-1 (uveal 
melanoma cell line) and ARPE19 (retinal pigment epithelium cell 
line). The results are summarized in Table 1. Among newly 
synthesized probes, 3 exhibited excellent inhibitory activity with 
GI50 value of 72 nM against HRECs in spite of the incorporation 
Scheme 4. Synthesis of photoaffinity probe (4b). Reagents and conditions: a) Boc-Tyr(Bn)-OH, EDCI, DMAP, rt, 72%; b) H2, Pd/C, EtOAc, 99%; 
c) K2CO3, benzyl 4-bromobutanoate, acetone, reflux; d) H2, Pd/C, EtOAc, 73% for 2 steps; e) 10, HBTU, iPr2NEt, DMF, 86%.
Scheme 3. Synthesis of photoaffinity probe (4a). Reagents and conditions: a) Boc-Tyr(Bn)-OH, EDCI, DMAP, rt , 94%; b) H2, Pd/C, EtOAc, 88%; 
c) K2CO3, benzyl bromoacetate, acetone, reflux; d) H2, Pd/C, EtOAc, 97% for 2 steps; e) 10, HBTU, iPr2NEt, DMF, 67%.
of the benzophenone photoreactive group and biotin reporter 
group. The probe 4a (GI50 = 210 nM) also retained potency 
comparable to cremastranone (1) and SH-11037 (2), but lost 
some specificity. In contrast, amide probe 4b and C-7 linking 
probe 5 had somewhat reduced activity on HREC cell 
proliferation. Therefore, the probes 3 and 4a would be very 
promising tools for target identification of antiangiogenic 
homoisoflavonoid-binding proteins. 
Table 1. Growth inhibitory activity (GI50, μM) of 
photoaffinity probes and their intermediates on the 
proliferation of microvascular (HREC), macrovascular 
(HUVEC) and other ocular (92-1, Y79 and ARPE19) cells. 
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shown in parentheses. cND, not determined. 
In conclusion, we have designed and synthesized novel 
photoaffinity probes of antiangiogenic homoisoflavonoids with 
photoreactive benzophenone and biotin. In order to search for the 
photoaffinity probes which retain potency, the attachment of 
benzophenone and biotin was on C3' and C-7 position of 
homoisoflavonoids. Among them, the probes 3 and 4a exhibited 
potent anti-proliferative and endothelial-cell specific activity 
when compared with the activity of the natural product 
cremastranone and improved analogue SH-11037. 
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Synthetic Methodology 
All starting materials and reagents were obtained from commercial suppliers and were used without 
further purification. Air and moisture sensitive reactions were performed under an argon atmosphere. 
Flash column chromatography was performed using silica gel 60 (230-400 mesh, Merck) with the 
indicated solvents. Thin-layer chromatography was performed using 0.25 mm silica gel plates 
(Merck). 1H and 13C NMR spectra were recorded on a Bruker 600 MHz spectrometer as solutions in 
deuteriochloroform (CDCl3) or methanol-d4. 
1H NMR data were reported in the order of chemical 
shift, multiplicity (s, singlet; d, doublet; t, triplet; m, multiplet and/or multiple resonances), number of 
protons, and coupling constant (J) in hertz (Hz). High-resolution mass spectra (HRMS) were recorded 
on a JEOL JMS-700 (FAB and EI) and an Agilent 6530 Q-TOF LC/MS/MS system (ESI).  
(4-hydroxyphenyl)(4-(prop-2-yn-1-yloxy)phenyl)methanone (6') 
S2 
To a solution of 4,4'-dihydroxybenzophone (500 mg, 2.33 mmol) in acetone (5.0 ml) at 0 °C, 
K2CO3 (161 mg, 1.17 mmol) and propargyl bromide (0.11 ml, 1.16 mmol) were added. The reaction 
mixture was stirred at 50 °C for 3 h, cooled to room temperature, and quenched with H2O (10 mL). 
The mixture was extracted three times with ethyl acetate. The combined extracts were washed with 
brine, dried over MgSO4, filtered, and concentrated. The residue was purified via Biotage (ethyl 
acetate / n-hexane = 1 : 2 Snap Ultra 25g column).  The desired fractions were collected and 
concentrated to give propargylated benzophenone (6') (240 mg, 82% BRSM). 1H-NMR (600 MHz, 
CD3OD) δ 7.73 (d, 2H, J = 8.4 Hz), 7.67 (d, 2H, J = 8.4 Hz), 7.09 (d, 2H, J = 9.0 Hz), 6.87 (d, 2H, J = 
9.0 Hz), 4.82 (s, 2H), 3.00 (t , 1H, J = 2.4 Hz); 13C-NMR (150 MHz, CD3OD) δ 195.4, 162.0, 161.0, 
132.3, 131.6, 131.1, 128.9, 114.7, 114.7, 77.8, 75.9, 55.3; HRMS (ESI): mass calcd for C16H15O3 [M 
+ H] +, 253.0786; found, 253.0872. 
tert-Butyl (3-(4-(4-(prop-2-yn-l-yloxy)benzoyl)phenoxy)propyl)carbamate  (7) 
To a THF solution (2 mL) of N-Boc-3-aminopropanol (117 mg, 0.76 mmol) were added the 
propargylated benzophenone (6') (140 mg, 0.56 mmol), PPh3 (150 mg, 0.76 mmol), and DIAD (130 
μL, 0.56 mmol) at room temperature. After stirring for 3 h at room temperature, the reaction mixture 
was diluted with ethyl acetate and the combined organic phase was washed with water and brine, 
dried over anhydrous MgSO4 and concentrated under reduced pressure. The residue was purified by 
flash column chromatography on silica gel (ethyl acetate / n-hexane = 1 : 3) to afford the dialkylated 
dihydroxybenzophenone (7) (160 mg, 70%). 1H-NMR (600 MHz, CDCl3) δ 7.77 (dd, 4H, J = 9.0 and 
5.0 Hz), 7.03 (d, 2H, J = 9.0 Hz), 6.93 (d, 2H, J = 9.0 Hz), 4.82 (bs, 1H), 4.75 (d, 2H, J = 1.2 Hz), 
4.09 (t , 2H, J = 6.0 Hz), 3.33 (m, 2H), 2.56 (t, 1H, J = 2.4 Hz), 2.01 (m, 1H), 1.42 (s, 9H), 1.25 (m, 
1H); 13C-NMR (150 MHz, CDCl3) δ 194.3, 162.1, 160.6, 156.0, 132.2, 132.1, 131.5, 130.6, 114.3, 
113.9, 77.8, 76.1, 65.9, 55.8, 37.8, 29.5, 28.4, 14.2; HRMS (ESI): mass calcd for C24H27NO5 [M + H]
 




To a THF solution (1.0 mL) of biotin-ONp (50 mg, 0.14 mmol) were added 11-azido-3,6,9-
trioxaundecan-l-amine (27 μL, 0.14 mmol) and Et3N (57 μL, 0.41 mmol) at room temperature. After 
stirring for 12 h at room temperature, the reaction mixture was quenched with H2O (1 mL). The 
reaction mixture was extracted three times with ethyl acetate and the combined organic phase was 
washed with brine, dried over anhydrous MgSO4, and concentrated under reduced pressure. The 
residue was purified by flash column chromatography on silica gel (MeOH / CH2Cl2 = 1 : 10) to 
afford the azide (8) (30 mg, 49%) 1H-NMR (600 MHz, CDCl3) δ 6.83 (m, 1H), 6.73 (m, 1H), 5.78 (m, 
1H), 4.50 (m, 1H), 4.30 (m, 1H), 3.65 (m, 8H), 3.62 (m, 2H), 3.56 (m, 2H), 3.42-3.37 (m, 4H), 3.13 
(m, 1H), 2.90 (m, 1H), 2.74 (d, 1H, J = 13 Hz), 2.22 (t, 2H, J = 7.8 Hz), 1.75-1.62 (m, 4H), 1.44-1.41 
(m, 2H); 13C-NMR (150 MHz, CDCl3) δ 173.4, 164.3, 70.6, 70.4, 70.0, 70.0, 69.9, 60.2, 55.7, 50.6, 
40.5, 39.1, 36.0, 28.3, 28.1, 25.56; HRMS (ESI): mass calcd for C18H32N6O5S [M + H]
 +, 445.2155; 
found, 445.3135. 
Boc-containing benzophenone-biotin (9). 
To a t-BuOH/H2O solution (2 mL, 1 : 1) of the benzophenone (7) (35 mg, 0.086 mmol) and the 
PEG-Biotin (8) (38 mg, 0.086 mmol), CuSO4·5H2O (2 mg, 0.086 mmol) and sodium ascorbate (1.0 M 
in H2O, 2 drops) were added at room temperature. After stirring at room temperature for 24 h, the 
reaction mixture was diluted with H2O (1 mL) and extracted with ethyl acetate and the combined 
organic phase was washed with brine, dried over anhydrous MgSO4, and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel (MeOH / CH2Cl2 = 
1 : 10) to afford the 1,2,3-triazole (30 mg, 40%). 1H-NMR (600 MHz, CDCl3) δ 7.86 (s, 1H), 7.77 (dd, 
4H, J = 8.4 and 2.4 Hz), 7.06 (d, 2H, J = 9.0 Hz), 6.94 (d, 2H, J = 8.4 Hz), 6.67 (bs, 1H), 6.45 (bs, 
1H), 5.49 (bs, 1H), 5.28 (s, 2H), 4.82 (bs, 1 Η), 4.57 (t, 2Η, J = 4.8 Hz), 4.47 (m, 1Η), 4.28 (m, 1Η), 
4.10 (t, 2Η, J = 6.0 Hz), 3.89 (t, 2H, J = 4.8 Hz), 3.65 (m, 2H), 3.60 (m, 2H), 3.56 (m, 6H), 3.52 (t, 2H, 
J = 4.8 Hz), 3.41-3.33 (m, 4H), 3.12 (m, 1H), 2.88 (m, 1H), 2.73 (m, 1H), 2.19 (t, 2H, J = 12 Hz), 
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2.03 (m, 2H), 1.75-1.58 (m, 6H), 1.43 (s, 9H), 1.41 (m, 2H); 13C-NMR (150 MHz, CDCl3) δ 194.4, 
173.2, 163.9, 162.1, 161.4, 156.0, 143.2, 132.2, 132.2, 131.2, 130.5, 124.3, 114.3, 113.9, 79.3, 70.6, 
70.5, 70.4, 70.3, 70.1, 69.9, 69.3, 65.9, 62.0, 61.7, 60.1, 55.5, 50.6, 50.3, 40.5, 39.1, 37.8, 35.9, 29.5, 
28.4, 28.1, 25.5; HRMS (ESI): mass calcd for C42H59N7O10S [M + H]
 +, 854.4044; found, 854.4143. 
Ammonium salt of benzophenone-biotin (10). 
To a CH2Cl2 solution (2 mL) of the Boc-protected benzophenone-biotin 9 (20 mg, 0.028 mmol) 
was added TFA (0.4 mL) at 0 °C. After stirring for 2.5 h at room temperature, the reaction mixture 
was concentrated under reduced pressure to afford the crude amine 10 (16 mg, 72%). The crude 
ammonium salt was used for the next reaction without further purification. 1H-NMR (600 MHz, 
CD3OD) δ 8.17 (s, 1H), 7.77 (d, 4H, J = 8.4 Hz), 7.16 (d, 2H, J = 8.4 Hz), 7.08 (d, 2H, J = 8.4 Hz), 
5.28 (s, 2H), 4.62 (m, 4H), 4.23 (t, 2H, J = 6.0 Hz), 3.91 (t, 2H, J = 5.0 Hz), 3.65 (m, 2H), 3.59-3.55 
(m, 8H), 3.48 (m, 2H), 3.18 (t, 2H, J = 12 Hz), 3.12-3.01 (m, 2H), 2.20 (m, 4H), 1.89 (m, 2H), 1.66 
(m, 4H); 13C-NMR (150 MHz, CD3OD) δ 165.1, 174.8, 164.7, 162.1, 161.8, 159.2, 158.9, 132.0, 
132.0, 130.7, 130.4, 125.1, 114.2, 113.9, 70.0, 70.0, 69.9, 69.8, 69.1, 68.8, 65.1, 62.0, 61.1, 60.3, 55.5, 
53.3, 50.2, 39.6, 38.9, 37.1, 35.3, 28.3, 28.0, 26.8, 25.4; HRMS (ESI): mass calcd for C37H51N7O8S[M 
+ H] +, 754.3520; found, 754.3623. 
tert-butyl 2-(2-methoxy-5-((5,6,7-trimethoxy-4-oxochroman-3-yl)methyl)phenoxy)acetate (12) 
To an acetone solution (5 mL) of 3-(3-hydroxy-4-methoxybenzyl)-5,6,7-trimethoxychroman-4-one 
(11) (102 mg, 0.272 mmol) were added tert-butyl bromoacetate (48 μL, 0.326 mmol) and K2CO3 (104 
mg, 0.816 mmol). After refluxing for 3 h, the reaction mixture was diluted with ethyl acetate and the 
combined organic phase was washed with water and brine, dried over MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl 
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acetate / n-hexane = 1 : 2) to afford the tert-butyl aryloxyacetate (12) (105 mg, 79%). 1H-NMR (600 
MHz, CDCl3) δ 6.78 (t, 2H, J = 8.4 Hz), 6.61 (d, 1H, J = 1.8 Hz), 6.16 (s, 1H), 4.51 (s, 2H), 4.20 (dd, 
1H, J = 11.4 and 4.2 Hz), 4.02 (dd, 1H, J =11.4 and 7.8 Hz), 3.88 (s, 3H), 3.81(s, 3H), 3.79 (s, 3H), 
3.74 (s, 3H), 3.11 (dd, 1H, J = 13.8 and 4.2 Hz), 2.66 (m, 1H), 2.55 (dd, 1H, J = 13.8 and 10.8 Hz); 
13C-NMR (150 MHz, CDCl3) δ 193.2, 169.6, 161.7, 161.3, 156.4, 150.2, 149.3, 139.4, 132.7, 124.4, 
116.6, 114.1, 110.6, 97.9, 84.1, 70.9, 68.4, 63.5, 63.2, 58.0, 58.0, 50.4, 34.3, 30.0, 30.0. 
2-(2-methoxy-5-((5,6,7-trimethoxy-4-oxochroman-3-yl)methyl)phenoxy)acetic acid (13) 
To a CH2Cl2 solution (2.0 mL) of the tert-butyl acetate (12) (66 mg, 0.135 mmol) was added TFA 
(0.7 mL). After stirring for 2.5 h at room temperature, the reaction mixture was concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH / 
CH2Cl2 = 1 : 10) to afford the aryloxyacetic acid (13) (62 mg, 84%). 
1H-NMR (600 MHz, CDCl3) δ 
6.83 (s, 2H), 6.77 (s, 1H), 6.24 (s, 1H), 4.70 (s, 2H), 4.25 (dd, 1H, J = 11.4 and 3.6 Hz), 4.09 (dd, 1H, 
J = 11.4 and 6 Hz), 3.89 (s, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 3.78 (s, 3H), 3.05 (dd, 1H, J = 13.2 and 
4.2 Hz), 2.75 (m, 1H), 2.69 (dd, 1H, J = 13.2 and 10.8 Hz); 13C-NMR (150 MHz, CDCl3) δ 194.1, 
173.5, 160.5, 160.4, 154.2, 148.3, 146.8, 137.1, 130.7, 123.8, 116.4, 112.3, 107.9, 96.2, 68.6, 66.8, 
61.8, 61.4, 56.2, 55.9, 48.0, 32.7; HRMS (ESI): mass calcd for C22H24O9 [M + Na]






To a DMF solution (1 mL) of the carboxylic acid (13) (24 mg, 0.044 mmol) were added HBTU (20 
mg, 0.051 mmol) and DIPEA (22 μL, 0.129 mmol). After stirring for 30 min, a DMF solution (0.5 
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mL) of the ammonium salt (9) (38 mg, 0.043 mmol) was added to the reaction mixture. After stirring 
for 24 h, the reaction mixture was diluted with ethyl acetate, dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on silica gel 
(MeOH / CH2Cl2 = 1 : 10) to afford the cremastranone-benzophenone-biotin (3) (16 mg, 32%). 
1H-
NMR (400 MHz, DMSO-d6) δ 8.21 (s, 1H), 8.01 (t,1H, J = 5.6 Hz), 7.78 (t, 1H, J = 5.6 Hz), 7.66 (dd, 
4H, J = 8.8 and 6.8 Hz), 7.16 (d, 2H, J = 8.8 Hz), 6.99 (d, 2H, J = 8.8 Hz), 6.89 (d, 1H, J = 8.4 Hz), 
6.80 (s, 1H), 6.77 (d, 1H, J = 8.4 Hz), 6.38 (s, 2H), 6.32 (s, 1H), 5.22 (s, 2H), 4.53 (t, 2H, J = 5.2 Hz), 
4.43 (s, 2H), 4.26-4.23 (m, 1H), 4.21 (dd, 1H, J = 11.2 and 4.4 Hz), 4.08-3.99 (m, 4H), 3.80 (d, 2H, J 
= 5.2 Hz), 3.77 (s, 3H), 3.71 (s, 3H), 3.69 (s, 3H), 3.60 (s, 3H), 3.50-3.47 (m, 2H), 3.44-3.42 (m, 6H), 
3.34-3.31 (m, 4H), 3.14 (q, 2H, J = 5.6 Hz), 3.05-3.01 (m, 1H), 2.99 (dd, 1H, J = 14.0 and 4.8 Hz), 
2.78-2.74 (m, 2H), 2.54 (d, 1H, J = 12.4 Hz), 2.00 (t, 2H, J = 7.2 Hz), 1.90 (t, 2H, J = 6.4 Hz), 
1.56(m, 1H), 1.48 (m, 3H), 1.24 (m, 2H); 13C-NMR (100 MHz, DMSO-d6) δ 193.5, 190.5, 172.5, 
168.3, 163.1, 162.2, 161.7, 159.5, 159.2, 153.9, 148.2, 147.5, 142.4, 137.2, 132.2, 132.1, 131.3, 130.6, 
130.2, 125.5, 122.8, 115.9, 114.8, 114.5, 112.6, 108.6, 96.8, 70.1, 70.0, 69.9, 69.5, 69.3, 69.0, 68.9, 
66.1, 61.7, 61.6, 61.4, 61.1, 59.5, 56.5, 55.9, 55.8, 49.8, 47.6, 40.2, 38.8, 35.8, 35.5, 31.8, 29.1, 28.6, 
28.4, 25.6; HRMS (ESI): mass calcd for C59H73N7O16S [M + H]
 +, 1168.4835; found, 1168.5145. 
2-Methoxy-5-((5′,6′,7′-trimethoxy-4′-oxochroman-3′-yl)methyl)phenyl (2S)-3-(4-
(benzyloxy)phenyl)-2-((tert-butoxycarbonyl)amino)propanoate (14).  
To a CH2Cl2 solution (2 mL) of 11 (63 mg, 0.16 mmol) were added Boc-Tyr(Bzl)-OH (75 mg, 0.19 
mmol), EDCI (40 mg, 0.24 mmol) and DMAP (4 mg, 0.03 mmol). After stirring for 17 h, the reaction 
mixture was diluted with CH2Cl2 and washed with water and brine, dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column chromatography on 
silica gel (ethyl acetate : n-hexane = 1 : 2) to afford the acylated 3-benzyl-chroman-4-one (14) (115 
mg, 94%). 1H-NMR (600 MHz, CDCl3) δ 7.39 (d, 2H, J = 7.2 Hz), 7.33 (t, 3H, J = 7.2 Hz), 7.28 (t, 
1H, J = 7.2 Hz), 7.19 (d, 2H, J = 8.4 Hz), 7.05 (dd, 1H, J = 8.4 and 1.8 Hz), 6.92 (m, 3H), 6.22 (d, 1H, 
J = 2.4 Hz), 5.01 (s, 2H), 4.80 (m, 1H), 4.26 (dd, 1H, J = 11.4 and 4.2 Hz), 4.06 (dd, 1H, J = 7.8 and 
3.6 Hz), 3.89 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.76 (s, 3H), 3.26 (dd, 1H, J = 14.4 and 6.0 Hz), 3.16 
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(dd, 1H, J = 13.8 and 4.2 Hz), 2.72 (m, 1H), 2.62 (m, 1H), 1.40 (s, 9H); 13C-NMR (150 MHz, CDCl3) 
δ 191.0, 170.1, 159.6, 159.3, 157.9, 155.0, 154.4, 149.6, 139.2, 137.5, 136.9, 131.0, 130.6, 128.5, 
128.2, 127.9, 127.6, 127.4, 123.4, 114.8, 112.6, 108.6, 96.0, 79.9, 70.0, 68.9, 61.6, 61.3, 56.0, 55.8, 
54.4, 48.2, 37.3, 31.8, 28.3; HRMS (ESI): mass calcd for C41H45NO11 [M + H]




A solution of 14 (161 mg, 0.22 mmol) and 10% Pd/C (23 mg) in ethyl acetate (3 mL) was placed 
under an atmosphere of hydrogen. After stirring for 48 h, the reaction mixture was diluted with ethyl 
acetate, filtered through a short pad of silica gel and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (ethyl acetate / n-hexane = 1 : 2) to afford 
(15) (112 mg, 88%). 1H-NMR (600 MHz, CDCl3) δ 7.10 (bs, 2H), 7.01(dd, 1H, J = 8.4 and 1.8 Hz), 
6.85 (m, 3H), 6.44 (bs, 1H), 6.25 (s, 1H), 5.10 (m, 1H), 4.80 (m, 1H), 4.25 (d, 1H, J = 9.0 Hz), 4.08 
(m, 1H), 3.92 (s, 3H), 3.86 (s, 3H), 3.79 (s, 3H), 3.75 (s, 3H), 3.17 (m, 1H), 3.09 (m, 1H), 3.03 (t, 1H, 
J = 10.2 Hz), 2.66 (m, 2H), 1.42 (s, 9H); 13C-NMR (150 MHz, CDCl3) δ 192.0, 170.3, 159.8, 159.7, 
155.5, 155.0, 154.4, 149.8, 139.2, 137.5, 130.9, 130.8, 127.6, 123.4, 115.8, 112.4, 108.4, 96.1, 80.1, 
68.6, 61.6, 61.3, 56.1, 55.9, 54.7, 53.4, 48.4, 38.0, 31.9, 28.3; HRMS (ESI): mass calcd for 
C34H39NO11 [M + H]
+, 638.2601; found, 638.2601. 
2-(4-((2S)-2-((tert-Butoxycarbonyl)amino)-3-(2-methoxy-5-((5,6,7-trimethoxy-4-oxochroman-3-
yl)methyl)phenoxy)-3-oxopropyl)phenoxy)acetic acid (16) 
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To an acetone (3 mL) solution of 15 (26 mg, 0.04 mmol), benzyl bromoacetate (10 μL, 0.08 mmol) 
and K2CO3 (16 mg, 0.12 mmol) were added. After stirring for 8 h at room temperature, the reaction 
mixture was diluted with ethyl acetate and the organic phase was washed with water and brine, dried 
over anhydrous MgSO4 and concentrated under reduced pressure. The residue was purified by flash 
column chromatography (ethyl acetate / n-hexanes = 1 : 1) to afford the benzyl ester (30 mg, 96%). 
And then a solution of benzyl ester (30 mg, 0.038 mmol) and 10% Pd/C (5 mg) in ethyl acetate (3 mL) 
was placed under an atmosphere of hydrogen. After stirring for 4 h, the reaction mixture was diluted 
with ethyl acetate, filtered through a short pad of silica gel and concentrated under reduced pressure. 
The residue was purified by flash column chromatography on silica gel (MeOH / CH2Cl2 = 1 : 10) to 
afford 16 (26 mg, 99%). 1H-NMR (400 MHz, DMSO-d6) δ 12.93 (bs, 1H), 7.42 (d, 1H, J = 8 Hz), 
7.21 (d, 2H, J = 8.4 Hz), 7.08 (q, 2H, J = 8.4 Hz), 6.85 (s, 1H), 6.82 (d, 2H, J = 8.4 Hz), 6.41 (s, 1H), 
4.59 (s, 2H), 4.33-4.28 (m, 1H), 4.27 (dd, 1H, J = 11.2 and 4.8Hz), 4.07 (t, 1H, J = 10 Hz), 3.79 (s, 
3H), 3.70 (s, 6H), 3.62 (s, 3H), 3.12 (dd, 1H, J = 13.6 and 4.4 Hz), 3.01 (dd, 1H, J = 14 and 5.2 Hz), 
2.92 (dd, 1H, J = 14.4 and 10 Hz), 2.85-2.78 (m, 1H), 2.60 (dd, 1H, J = 13.6 and 9.2 Hz), 1.31 (s, 
9H); 13C-NMR (100 MHz, DMSO-d6) δ 190.5, 170.8, 170.7, 159.6, 159.3, 156.9, 155.9, 154.0, 149.7, 
139.4, 137.3, 136.8, 131.5, 130.6, 130.3, 123.5, 114.6, 113.4, 108.6, 96.9, 78.8, 69.4, 64.9, 61.7, 61.7, 









To a solution of 16 (16 mg, 0.023 mmol) in DMF (1 mL) at room temperature were added HBTU 
(10 mg, 0.027 mmol) and DIPEA (12 μL, 0.069 mmol). The reaction mixture was stirred at room 
temperature for 0.5 h and a solution of benzophenone-biotin amine (10) (20 mg, 0.023 mmol) in DMF 
(0.5 mL) was added to the mixture. The resulting mixture was stirred at room temperature for 18 h 
and quenched at 0 ºC with H2O. The mixture was extracted three times with ethyl acetate and the 
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combined extracts were washed with brine, dried over anhydrous MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH / 
CH2Cl2 = 1 : 30) to afford the amide (4a) (22 mg, 67%). 
1H-NMR (400 MHz, DMSO-d6) δ 8.20 (s, 
1H), 8.17 (t, 1H, J = 6Hz), 7.78 (t, 1H, J = 6Hz), 7.67 (d, 4H, J = 8 Hz), 7.42 (d, 1H, J = 8 Hz), 7.23 
(d, 2H, J = 8.4 Hz), 7.16 (d, 2H, J = 8.8 Hz), 7.07-7.00 (m, 4H), 6.88-6.85 (m, 3H), 6.41 (s, 1H), 6.37 
(s, 1H), 6.31 (s, 1H), 5.21 (s, 2H), 4.52 (t, 2H, J = 5.6 Hz), 4.41 (s, 2H), 4.29 (m, 1H), 4.26-4.22 (m, 
2H), 4.08-4.01 (m, 4H), 3.79 (m, 5H), 3.69 (s, 6H), 3.61 (s, 3H), 3.49-3.47 (m, 2H), 3.44-3.42 (m, 5H), 
3.34 (t, 2H, J = 6 Hz), 3.27 (d, 2H, J = 2 Hz), 3.13 (d, 2H, J = 6 Hz), 3.08 (m, 1H), 3.05 (m, 1H), 
3.00-2.99 (m, 1H), 2.97-2.95 (m, 1H), 2.92-2.86 (m, 1H), 2.80 (m, 1H), 2.78 (dd, 1H, J = 16.8 and 4.8 
Hz), 2.59-2.56 (m, 1H), 2.54 (d, 1H, J = 12.4 Hz), 2.02 (t, 2H, J = 6.8 Hz), 1.90 (t, 2H, J = 6.4 Hz), 
1.56-1.52 (m, 1H), 1.44 (m, 3H), 1.30 (s, 9H), 1.24 (m, 2H); 13C-NMR (100 MHz, DMSO-d6) δ 193.5, 
190.4, 172.5, 170.8, 168.1, 163.1, 162.3, 161.7, 159.5, 159.2, 156.8, 155.8, 154.0, 149.6, 142.4, 139.3, 
137.2, 132.2, 132.1, 131.4, 130.7, 130.6, 130.5, 130.2, 125.5, 123.4, 114.9, 114.8, 114.6, 113.3, 108.6, 
96.8, 78.8, 70.1, 70.0, 69.9, 69.5, 69.3, 69.0, 67.5, 66.1, 61.7, 61.7, 61.7, 61.4, 61.2, 59.6, 56.6, 56.2, 
55.9, 55.8, 49.8, 47.5, 40.2, 38.8, 35.9, 35.8, 35.5, 31.3, 29.1, 28.6, 28.5, 28.4, 28.2, 25.6; HRMS 
(ESI): mass calcd for C73H90N8O20S [M + H]
+, 1431.6070; found, 1431.6067. 
tert-Butyl ((2S)-3-(4-(benzyloxy)phenyl)-1-((2-methoxy-5-((5,6,7-trimethoxy-4-oxochroman-3-
yl)methyl)phenyl)amino)-1-oxopropan-2-yl)carbamate (18) 
To a CH2Cl2 solution (6 mL) of 17 (35 mg, 0.09 mmol) were added Boc-Tyr(Bn)-OH (35 mg, 0.09 
mmol), EDCI (18 mg, 0.1 mmol) and DMAP (2 mg, 0.01 mmol). After stirring for 17 h, the reaction 
mixture was diluted with CH2Cl2 and washed with water and brine, dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The residue was purified by flash column chromatography on 
silica gel (ethyl acetate / n-hexane = 1 : 2) to afford 18 (50 mg, 72%). 1H-NMR (600 MHz, CDCl3) δ 
8.22 (s, 1H), 8.10 (bs, 1H), 7.41 (d, 2H, J = 7.8 Hz), 7.37 (t, 2H, J = 7.2 Hz), 7.31 (t, 1H, J = 7.2 Hz), 
7.16 (d, 2H, J = 8.4 Hz), 6.90 (d, 3H, J = 8.4 Hz), 6.75 (d, 1H, J = 7.8 Hz), 6.24 (s, 1H), 5.01 (s, 2H), 
4.46 (bs, 1H), 4.29 (dd, 1H, J = 10.8 and 3.6 Hz), 4.12 (m, 1H), 3.92 (s, 3H), 3.85 (s, 3H), 3.80 (s, 
3H), 3.73 (s, 3H), 3.23 (dd, 1H, J = 14.4 and 3.6 Hz), 3.10 (m, 2H), 2.81 (m, 1H), 2.63 (m, 1H), 1.42 
(s, 9H); 13C-NMR (150 MHz, CDCl3) δ 191.3, 169.4, 159.7, 159.2, 157.8, 154.4, 146.7, 137.4, 136.9, 
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131.0, 130.3, 128.5, 127.9, 127.4, 127.0, 124.4, 120.3, 115.0, 110.0, 108.7, 96.0, 70.0, 69.2, 69.2, 61.6, 
61.3, 56.0, 55.6, 48.3, 48.3, 37.7, 32.2, 30.9, 29.7, 28.2; HRMS (ESI): mass calcd for C41H46N2O10 [M 
+ H]+, 727.3230; found, 727.3228. 
tert-Butyl (3-(4-hydroxyphenyl)-1-((2-methoxy-5-((5,6,7-trimethoxy-4-oxochroman-3-
yl)methyl)phenyl)amino)-1-oxopropan-2-yl)carbamate (19) 
A solution of 18 (50 mg, 0.068 mmol) and 10% Pd/C (8 mg) in ethyl acetate (3 mL) was placed 
under an atmosphere of hydrogen. After stirring for 17 h, the reaction mixture was diluted with ethyl 
acetate, filtered through a short pad of silica gel and concentrated under reduced pressure. The residue 
was purified by flash column chromatography on silica gel (ethyl acetate / n-hexane = 1 : 2) to afford 
19 (43 mg, 99%). 1H-NMR (600 MHz, CDCl3) δ 8.13 (s, 1H), 8.03 (bs 1H), 7.06 (d, 2H, J = 8.4 Hz), 
6.80 (d, 1H, J = 7.8 Hz), 6.72 (m, 3H), 5.14 (bs, 1H), 4.42 (bs, 1H), 4.14 (dd, 1H, J = 10.4 and 1.8 
Hz), 3.95 (d, 1H, J = 12.4 Hz), 3.88 (d, 3H, J = 6.6 Hz), 3.80 (t, 6H, J = 1.2 Hz), 3.73 (d, 3H, J = 1.8 
Hz), 3.15 (m, 2H), 2.50 (dd, 1H, J = 13.8 Hz), 2.40 (m, 1H), 2.25 (t, 1H, J = 7.8 Hz), 1.41 (s, 9H); 
13C-NMR (150 MHz, CDCl3) δ 191.6, 169.6, 159.8, 159.3, 155.5, 155.3, 154.3, 146.9, 137.3, 130.8, 
130.3, 127.7, 126.9, 124.6, 120.5, 115.7, 110.0, 108.6, 96.0, 80.3, 69.2, 61.6, 61.3, 56.9, 56.1, 55.7, 
48.3, 37.8, 32.3, 28.2; HRMS (ESI): mass calcd for C34H40N2O10 [M + H]
+, 637.2761; found, 
637.2758. 
4-(4-((2S)-2-((tert-Butoxycarbonyl)amino)-3-((2-methoxy-5-((5,6,7-trimethoxy-4-oxochroman-3-
yl)methyl)phenyl)amino)-3-oxopropyl)phenoxy)butanoic acid (20) 
To an acetone (3 mL) solution of 19 (77 mg, 0.067 mmol), benzyl 4-bromobutanoate (28 mg, 0.1 
mmol) and K2CO3 (30 mg, 0.2 mmol) were added. After refluxing for 24 h, the reaction mixture was 
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diluted with ethyl acetate and the organic phase was washed with water and brine, dried over 
anhydrous MgSO4 and concentrated under reduced pressure. The residue was purified by flash 
column chromatography (ethyl acetate / n-hexanes = 1 : 1) to afford the benzyl butanoate 19' (35 mg, 
64%). 1H-NMR (600 MHz, CD3OD) δ 8.21 (s, 1H), 8.04 (bs, 1H), 7.33-7.23 (m, 5H), 7.11 (d, 2H, J = 
8.4 Hz), 6.88 (d, 1H, J = 7.8 Hz), 6.77 (d, 2H, J = 8.4 Hz), 6.73 (d, 1H, J = 7.8 Hz), 6.23 (d, 1H, J = 
1.8 Hz), 5.10 (s, 2H), 4.42 (bs, 1H), 4.28 (dd, 1H, J = 10.8 and 3.6 Hz), 3.94 (t, 2H, J = 6 Hz), 3.90 (s, 
3H), 3.85 (s, 3H), 3.79 (s, 3H), 3.71 (s, 3H), 3.22 (dd, 1H, J = 13.8 and 3.6 Hz), 3.09 (bs, 1H), 3.03 
(bs, 1H), 2.78-2.74 (m, 1H), 2.61(t, 1H, J = 13.8 Hz), 2.55 (t, 2H, J = 7.2 Hz), 2.10 (m, 2H), 1.41 (s, 
9H); 13C-NMR (150 MHz, CD3OD) δ 191.3, 173.0, 171.1, 169.3, 159.7, 159.2, 154.4, 146.7, 137.4, 
135.9, 131.0, 130.3, 128.5, 128.2, 128.2, 124.4, 120.3, 114.7, 110.0, 108.7, 96.0, 69.2, 66.6, 66.3, 61.6, 
61.3, 60.4, 56.1, 55.6, 53.4, 48.3, 48.3, 37.7, 32.2, 31.5, 30.8, 28.3, 24.6, 22.6.   
A solution of the benzyl butanoate 19' (30 mg, 0.036 mmol) and 10% Pd/C (10 mg) in ethyl acetate 
(3 mL) was placed under an atmosphere of hydrogen. After stirring for 2 h, the reaction mixture was 
diluted with ethyl acetate, filtered through a short pad of silica gel and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel (ethyl acetate / n-
hexane = 1 : 1) to afford 20 (23 mg, 86%). 1H-NMR (400 MHz, DMSO-d6) δ 9.04 (s, 1H), 7.89 (s, 
1H), 7.23 (d, 1H, J = 7.6 Hz), 7.18 (d, 2H, J = 7.6 Hz), 6.96 (d, 1H, J = 8.4 Hz), 6.90 (d, 1H, J = 8.4 
Hz), 6.80 (d, 2H, J = 7.6 Hz), 6.42 (s, 1H), 4.26 (m, 2H), 4.10-4.06 (m, 1H), 3.90 (t, 2H, J = 6 Hz), 
3.80 (s, 3H), 3.78 (s, 3H), 3.70 (s, 3H), 3.62 (s, 3H), 2.98-2.95 (m, 2H), 2.71 (m, 2H), 2.57 (m, 1H), 
2.23 (t, 2H, J = 6.8 Hz), 1.86 (t, 2H, J = 6.8 Hz), 1.30 (s, 9H). A carboxylic acid proton in the butyric 
acid linked to tyrosine moiety was not observed; 13C-NMR (100 MHz, DMSO-d6) δ 190.5, 171.0, 
159.6, 159.3, 157.6, 155.9, 154.0, 137.2, 130.7, 130.6, 130.2, 130.2, 127.3, 121.7, 121.6, 121.6, 114.5, 
111.5, 108.6, 96.9, 78.8, 69.3, 67.3, 61.7, 61.2, 57.2, 56.6, 56.3, 48.0, 36.4, 32.1, 31.7, 28.6, 25.3; 
HRMS (ESI): mass calcd for C38H46N2O12 [M + H]







To a solution of 20 (20 mg, 0.028 mmol) in DMF (1 mL) at room temperature were added HBTU 
(13 mg, 0.033 mmol) and DIPEA (15 μL, 0.084 mmol). The reaction mixture was stirred at room 
temperature for 0.5 h and a solution of benzophenone-biotin amine (9) (24 mg, 0.028 mmol) in DMF 
(0.5 mL) was added to the mixture. The resulting mixture was stirred at room temperature for 18 h 
and quenched at 0 ºC with H2O. The mixture was extracted three times with ethyl acetate and the 
combined extracts were washed with brine, dried over anhydrous MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH / 
CH2Cl2 = 1 : 30) to afford the amide (4b) (36 mg, 87%). 
1H-NMR (400 MHz, DMSO-d6) δ 9.04 (s, 
1H), 8.20 (s, 1H), 7.94 (t, 1H, J = 5.2 Hz), 7.88 (s, 1H), 7.78 (t, 1H, J = 5.2 Hz), 7.67 (d, 4H, J = 7.6 
Hz), 7.23 (d, 1H, J = 8 Hz), 7.18 (t, 4H, J = 8.8 Hz), 7.03 (d, 2H, J = 8.8 Hz), 6.95 (d, 1H, J = 8 Hz), 
6.90 (d, 1H, J = 8.4 Hz), 6.79 (d, 2H, J = 8 Hz), 6.42 (s, 1H), 6.38 (s, 1H), 6.32 (s, 1H), 5.22 (s, 2H), 
4.52 (t, 2H, J = 4.8 Hz), 4.26 (m, 3H), 4.10-4.02 (m, 4H), 3.88 (t, 2H J = 6 Hz), 3.80 (s, 4H), 3.77 (s, 
3H), 3.70 (s, 3H), 3.62 (s, 3H), 3.48 (d, 2H, J = 4.4 Hz), 3.42 (s, 5H), 3.30 (s, 8H), 3.19 (d, 2H, J = 
5.6 Hz), 3.13 (d, 2H, J = 5.6 Hz), 3.03 (m, 1H), 2.98 (d, 2H, J = 13.2 Hz), 2.78-2.70 (m, 3H), 2.57 (m, 
2H), 2.21 (t, 2H, J = 7.2 Hz), 2.02 (t, 2H, J = 7.2 Hz), 1.87 (t, 4H, J = 6.4 Hz), 1.52 (m, 1H), 1.46-
1.44 (m, 3H), 1.29 (s, 9H), 1.22-1.20 (m, 2H); 13C-NMR (100 MHz, DMSO-d6) δ 193.5, 190.5, 172.5, 
172.0, 171.0, 163.1, 162.3, 161.7, 159.6, 159.3, 157.5, 155.9, 154.1, 142.4, 137.3, 132.3, 132.2, 130.8, 
130.8, 130.7, 130.6, 130.6, 130.3, 127.3, 125.6, 124.9, 114.9, 114.6, 114.5, 111.4, 108.6, 96.9, 78.8, 
70.1, 70.0, 69.9, 69.6, 69.3, 69.1, 67.2, 66.0, 61.8, 61.8, 61.7, 61.7, 61.4, 61.2, 59.6, 57.2, 56.6, 56.3, 
56.3, 55.8, 49.9, 48.0, 38.8, 35.8, 35.5, 32.2, 32.1, 31.8, 29.2, 28.6, 28.5, 28.4, 25.7, 25.4; HRMS 
(ESI): mass calcd for C75H95N9O19S [M + H]




To a solution of 1-(4-(benzyloxy)-6-hydroxy-2,3-dimethoxyphenyl)ethanone 21 (100 mg, 0.33 
mmol) in toluene (2.0 mL) was added N,N-dimethylformamide dimethyl acetal (0.052 mL, 0.39 
mmol). After stirring for 18 h at 80 °C, the mixture was cooled to 0 °C and c-HCl (0.2 mL) was 
added. After stirring for 1 h at 50 °C, The reaction mixture was diluted with ethyl acetate and the 
organic phase was washed with water and brine, and dried over anhydrous MgSO4. The solvent was 
removed under reduced pressure and purified by flash column chromatograph on silica gel (ethyl 
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acetate : n-hexane = 1 : 2) to afford 7-(benzyloxy)-5,6-dimethoxy-4H-chromen-4-one 21' (101 mg, 
97%). 1H-NMR (CDCl3, 600 MHz) δ 7.63 (d, 1H, J = 6.0 Hz), 7.46-7.40 (m, 4H), 7.37 (t, 1H, J = 6.6 
Hz), 6.7 (s, 1H), 6.1 (d, 1H, J = 6.0 Hz), 5.20 (s, 2H), 3.97 (s, 3H) , 3.92 (s, 3H); 13C-NMR (150 MHz, 
CDCl3) δ 176.2, 156.8, 154.6, 152.9, 140.7, 135.5, 128.8, 128.4, 127.2, 114.2, 113.8, 97.6, 70.9, 62.1, 
61.5, 30.9.  
An anhydrous MeOH solution of chromen-4-one 21' (46.8 mg, 0.15mmol) and 10% Pd/C (15.9mg) 
was placed under an atmosphere of hydrogen. After stirring for 1 h, the reaction mixture was diluted 
with EtOAc, filtered through a Celite pad and concentrated under reduced pressure. The residue was 
purified by flash column chromatography on silica gel (ethyl acetate / n-hexanes = 1 : 2) to afford the 
hydrogenated compound 22 (33 mg, 99%).; 1H-NMR (CDCl3, 600 MHz) δ 6.31 (s, 2H), 4.43 (t, 2H, J 
= 6.6 Hz), 3.90 (s, 3H), 3.90 (s, 3H), 2.72 (d, 2H, J = 6.6 Hz). 13C-NMR (150 MHz, CDCl3) δ 189.3, 
160.1, 155.5, 153.3, 135.1, 109.6, 98.9, 66.6, 61.5, 61.4, 38.7; HRMS (ESI): mass calcd for C11H12O5 
[M + H] +, 224.0685; found, 224.0677. 
Benzyl 4-((5,6-dimethoxy-4-oxochroman-7-yl)oxy)butanoate (23) 
To an acetone (3 mL) solution of 7-hydroxy-5,6-dimethoxychroman-4-one (22) (77 mg, 0.34 
mmol), benzyl 4-bromobutanoate (88 mg, 0.34 mmol) and K2CO3 (142 mg, 1.0 mmol) were added. 
After refluxing for 24 h, the reaction mixture was diluted with ethyl acetate and the organic phase was 
washed with water and brine, dried over anhydrous MgSO4 and concentrated under reduced pressure. 
The residue was purified by flash column chromatography (ethyl acetate / n-hexanes = 1 : 2) to afford 
the butanoate (23) (110 mg, 80%). 1H-NMR (600 MHz, CDCl3) δ 7.30 (s, 5H), 6.18 (s, 1H), 5.09 (s, 
2H), 4.39 (t, 2H, J = 6.0 Hz), 4.01 (t, 2H, J = 6.0 Hz), 3.87 (s, 3H), 3.73 (s, 3H), 2.67 (t, 2H, J = 6.0 
Hz), 2.57 (t, 2H, J = 7.2 Hz), 2.17 (m, 2H); 13C-NMR (150 MHz, CDCl3) δ 189.1, 172.6, 159.9, 158.5, 
154.4, 137.4, 135.8, 128.5, 128.3, 128.2, 109.6, 96.8, 67.5, 66.8, 66.4, 61.6, 61.2, 38.7, 30.5, 24.2; 
HRMS (EI): mass calcd for C22H24O7 [M + H]




To solution of butanoate (23) (56 mg, 0.139 mmol) in benzene (2 mL) was added isovanillin (22 
mg, 0.139 mmol) and p-toluenesulfonic acid (3 mg, 0.01 mmol) at 0 °C. The reaction mixture was 
refluxed for 20 h. After cooling to room temperature, the reaction mixture was concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl 
acetate : n-hexane = 1 : 2) to afford 24 (40 mg, 54%). 1H-NMR (600 MHz, CDCl3) δ 7.71 (s, 1H), 
7.32 (m, 5H), 6.88 (d, 1H, J = 8.4 Hz), 6.85 (d, 1H, J = 1.8 Hz), 6.83 (dd, 1H, J = 8.4 and 1.8 Hz), 
6.19 (s, 1H), 5.21 (s, 2H), 5.11 (s, 2H), 4.04 (t, 2H, J = 6.0 Hz), 3.95(s, 3H), 3.92 (s, 3H), 3.77 (s, 3H), 
2.59 (t, 2H, J = 7.2 Hz), 2.19 (m, 2H); 13C-NMR (150 MHz, CDCl3) δ 179.5, 172.7, 159.3, 158.4, 
154.8, 147.5, 145.5, 137.9, 136.2, 135.8, 130.2, 128.6, 128.3, 128.2, 128.1, 123.2, 115.7, 110.7, 110.5, 
96.9, 67.6, 67.5, 66.4, 61.6, 61.3, 56.0, 30.5, 24.3; HRMS (ESI): mass calcd for C30H30O9 [M + H]
+, 
535.1968; found, 535.1987. 
4-((3-(3-(((tert-Butoxycarbonyl)-L-phenylalanyl)oxy)-4-methoxybenzyl)-5,6-dimethoxy-4-
oxochroman-7-yl)oxy)butanoic acid (25) 
To a CH2Cl2 solution (2 mL) of benzylidene (24) (18.8 mg, 0.035 mmol) were added Boc-Phe-OH 
(10 mg, 0.035 mmol), EDCI (8 mg, 0.052 mmol) and DMAP (1 mg, 0.007 mmol). After stirring for 
17 h, the reaction mixture was diluted with CH2Cl2 and washed with water and brine, dried over 
anhydrous MgSO4 and concentrated under reduced pressure. The residue was purified by flash column 
chromatography on silica gel (ethyl acetate / n-hexane = 1 : 2) to afford the acylated benzylidene 24' 
(19 mg, 70%). 1H-NMR (600 MHz, CDCl3) δ 7.70 (s, 1H), 7.33(m, 10H), 7.16 (dd, 1H, J = 9.0 and 
2.4 Hz), 7.00 (d, 1H, J = 9.0 Hz), 6.87 (s, 1H), 6.21 (s, 1H), 5.16 (d, 2H, J = 1.8 Hz), 5.12 (s, 2H), 
4.88 (m, 1H), 4.05 (t, 2H, J = 6.6 Hz), 3.96 (s, 3H), 3.85 (s, 3H), 3.78 (s, 3H), 3.32 (dd, 1H, J = 14.4 
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and 6.0 Hz), 3.22 (dd, 1H, J = 13.8 and 6.0 Hz), 2.60 (t, 2H, J = 7.2 Hz), 2.20 (m, 2H), 1.41(s, 9H); 
13C-NMR (150 MHz, CDCl3) δ 179.3, 172.7, 171.1, 170.0, 159.3, 158.5, 154.9, 151.8, 139.2, 137.9, 
135.8, 134.9, 130.7, 129.5, 128.6, 128.3, 128.2, 127.5, 127.1, 124.1, 112.4, 110.6, 96.9, 67.6, 67.4, 
66.4, 61.6, 61.3, 55.9, 54.3, 38.2, 31.5, 30.5, 29.9, 29.7, 28.3, 28.1, 24.3; HRMS (ESI): mass calcd for 
C44H47NO12 [M + H]
+, 782.3175; found, 782.3164. 
A solution of the acylated benzylidene 24' (19 mg, 0.024 mmol) and 10% Pd/C (4 mg) in ethyl 
acetate (2 mL) was placed under an atmosphere of hydrogen. After stirring for 24 h, the reaction 
mixture was diluted with ethyl acetate, filtered through a short pad of silica gel and concentrated 
under reduced pressure. The residue was purified by flash column chromatography on silica gel (ethyl 
acetate / n-hexane = 1 : 2) to afford the butanoic acid (25) (16 mg, 99%). 1H-NMR (600 MHz, CDCl3) 
δ 7.32 (m, 5H), 7.05 (d, 1H, J = 7.8 Hz), 6.89 (d, 1H, J = 8.4 Hz), 6.80 (s, 1H), 6.24 (s, 1H), 4.85 (m, 
1H), 4.24(dd, 1H, J = 11.4 and 3.6 Hz), 4.07 (m, 3H), 3.90 (s, 3H), 3.78 (s, 3H), 3.77 (s, 3H), 3.32 (dd, 
1H, J = 7.8 Hz), 3.20 (m, 2H), 2.70 (m, 1H), 2.60 (t, 1H, J = 12 Hz), 2.43 (t, 2H, J = 7.2 Hz), 2.15 (m, 
2H). A carboxylic acid proton in the C7-butyric acid moiety was not observed; 13C-NMR (150 MHz, 
CDCl3) δ 191.0, 177.4, 170.1, 159.6, 159.0, 155.0, 154.4, 149.6, 139.2, 137.6, 136.0, 131.1, 129.6, 
128.5, 127.6, 127.0, 123.3, 112.6, 108.4, 96.7, 79.9, 68.9, 68.5, 65.0, 61.6, 61.2, 55.8, 54.3, 52.0, 48.2, 
40.8, 38.2, 32.3, 31.9, 29.7, 29.6, 28.3, 25.1; HRMS (ESI): mass calcd for C37H43NO12 [M + H]
+, 





(tert-butoxycarbonyl)-L-phenylalaninate (5)  
 
To a solution of 25 (12 mg, 0.016 mmol) in DMF (1 mL) at room temperature were added HBTU 
(9 mg, 0.019 mmol) and DIPEA (2 μL, 0.048 mmol). The reaction mixture was stirred at room 
temperature for 0.5 h and a solution of benzophenone-biotin amine (9) (14 mg, 0.016 mmol) in DMF 
(0.5 mL) was added to the mixture. The resulting mixture was stirred at room temperature for 18 h 
and quenched at 0 ºC with H2O. The mixture was extracted three times with ethyl acetate and the 
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combined extracts were washed with brine, dried over anhydrous MgSO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography on silica gel (MeOH / 
CH2Cl2 = 1 : 30) to afford the amide (5) (8.2 mg, 36%). 
1H-NMR (400 MHz, CDCl3) δ 7.86 (s, 1H), 
7.75 (dd, 4H, J = 8.8 and 2.8 Hz), 7.31-7.25 (m, 4H), 7.05 (d, 3H, J = 8.8 Hz), 6.91 (t, 3H, J = 8.4 
Hz), 6.80 (s, 1H), 6.53 (s, 1H), 6.22 (s, 1H), 6.18 (s, 1H), 5.91 (s, 1H), 5.26 (s, 2H), 5.04 (d, 1H, J = 8 
Hz), 4.84 (d, 1H, J = 6.8 Hz), 4.56 (t, 2H, J = 4.8 Hz), 4.45 (m, 1H), 4.25 (m, 2H), 4.08 (m, 4H), 3.88 
(m, 5H), 3.77 (s, 3H), 3.77 (s, 3H), 3.64-3.53 (m, 10H), 3.48-3.44 (m, 4H), 3.39 (t, 2H, J = 5.2 Hz), 
3.33 (dd, 1H, J = 14.4 and 6 Hz), 3.21-3.09 (m, 4H), 2.86 (m, 1H), 2.72 (m, 2H), 2.61 (m, 1H), 2.42 
(t, 2H, J = 7.6 Hz), 2.18-2.12 (m, 4H), 2.03-1.98 (m, 2H), 1.63-1.56 (m, 4H), 1.46-1.39 (m, 11H); 13C-
NMR (100 MHz, CDCl3) δ 194.3, 191.0, 173.5, 172.3, 171.1, 170.1, 164.0, 162.0, 161.4, 159.7, 
158.5, 154.4, 149.6, 143.1, 139.2, 137.4, 136.0, 132.2, 132.2, 131.0, 131.0, 130.5, 129.6, 128.5, 127.6, 
127.0, 124.4, 123.3, 114.3, 113.9, 112.6, 108.6, 96.9, 79.9, 70.4, 70.3, 70.2, 70.0, 69.9, 69.8, 69.3, 
68.9, 68.0, 66.1, 61.9, 61.8, 61.7, 61.3, 60.4, 60.2, 55.8, 55.5, 54.3, 50.6, 50.3, 48.1, 42.5, 40.4, 39.1, 
38.2, 36.9, 35.7, 32.6, 31.7, 29.0, 28.3, 28.1, 25.5, 24.8; HRMS (ESI): mass calcd for 
C74H92N8O19SNa [M + Na]




LC-MS analysis of four photoaffinity probes 
LC-MS data were obtained using a Waters system (Waters 2489 UV/Visible Detector, Waters 3100 
Mass, Waters 515 HPLC pump, Waters 2545 Binary Gradient Module, Waters Reagent Manager, and 
Waters 2767 Sample Manager) by using SunFire C18 column (4.6 × 50 mm, 5 μm particle size), 
isocratic elution at 40% acetonitrile in water for 60 min; ﬂow rate: 1.4 mL/min  
LC conditions MS conditions 
System：Waters Alliance HPLC system 
Detection: PDA detector 
Flow rate: 1.4 mL/min 
Mobile phase A: H2O 
Mobile phase B: Acetonitrile 
Column: Sunfire C18 5.0 µm 4.6 x 50 mm Column 
Sample diluent: DMSO 
Injection volume: 10 µL 
PDA scan range: 200 to 600 nm 
Data management: MassLynx Software 
Isocratic: 40% Acetonitrile in H2O 
System: Waters 3100 mass detector 
Mode: Positive electrospray (ES+) 
Capillary: 3.5 kV 
Cone: 50 V 
Extractor: 1 V 
RF Lens: 0.1 V 
Source temp.: 120 °C 
Desolvation temp.: 350 °C 










EBM-2 and IMDM growth media were purchased from Lonza (Walkersville, MD, USA). RPMI and 
Ham’s/F-10 media were purchased from Thermo Scientific (Waltham, MA, USA). HRECs and 
Attachment Factor were purchased from Cell Systems (Kirkland, WA, USA). Clonetics® HUVECs 
were purchased from Lonza. All endothelial cells were used between passages 5 and 8. Endothelial 
Growth Medium (EGM-2) was prepared by mixing the contents of an EGM-2 “Bullet Kit” (Cat. no. 
CC-4176) with Endothelial Basal Medium (EBM) (Lonza). The EGM-2 “Bullet Kit” contains 
hydrocortisone, human fibroblast growth factor, vascular endothelial growth factor, R3-insulin like 
growth factor, ascorbic acid, human epidermal growth factor, gentamycin and heparin along with 2% 
fetal bovine serum (FBS). 92-1 cells1 (a kind gift from Dr. Martine Jager) were grown in RPMI 
medium containing 10% FBS and 1% penicillin-streptomycin (pen-strep). Y79 cells2 (a kind gift from 
Dr. Brenda Gallie) were grown in RB medium (IMDM + 10% FBS + 55 µM β-mercaptoethanol + 10 
µg/mL insulin + 1% pen-strep). ARPE19 cells (ATCC, Manassas, VA, USA) were grown in 
Ham’s/F-10 + 10% FBS + 1% pen-strep. Identity of 92-1 and Y79 cell lines was confirmed by short 
tandem repeat profiling. 
Cell Proliferation Assay 
The proliferation of cells was monitored by an alamarBlue based fluorescence assay. Five 
cell types were used: HRECs, HUVECs, 92-1, Y79 and ARPE19. Briefly, 2,500 cells in 100 
µL growth medium were incubated in 96-well clear bottom black plates for 24 hours 
followed by 48 hours’ incubation with different concentrations of each test compound (range: 
0.5 nM to 500 µM). At the end of the incubation, 11.1 µL of alamarBlue reagent was added 
and 4 hours after, fluorescence readings were taken with excitation and emission wavelengths 
of 560 nm and 590 nm respectively. Data were analyzed and dose response curves generated 
using GraphPad Prism software (v. 6.0). Only those compounds that reduced cell number by 
50% or more at the highest concentration tested (relative to DMSO control) were reported as 
having a GI50 < 100 µM. 
1. I. De Waard-Siebinga, D. J. Blom, M. Griffioen, P. I. Schrier, E. Hoogendoorn, G.
Beverstock, E. H. Danen and M. J. Jager, Int. J. Cancer, 1995, 62, 155-161.
2. T. W. Reid, D. M. Albert, A. S. Rabson, P. Russell, J. Craft, E. W. Chu, T. S. Tralka and J. L.
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